COST-EFFECTIVENESS ANALYSIS OF NIRMATRELVIR/RITONAVIR COMPARED WITH MOLNUPIRAVIR IN PATIENTS AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19 IN JAPAN

被引：0
|
作者：
Yuasa, A. [1 ]
Matsuda, H. [2 ]
Fujii, Y. [3 ]
Kado, Y. [2 ]
Murata, K. [1 ]
Yoshida, M. [3 ]
Mugwagwa, T. [4 ]
Gu, Y. [5 ]
机构：
[1] Pfizer Japan Inc, Shibuya Ku, Tokyo, Japan
[2] IQVIA Solut Japan GK, Minato Ku, Tokyo, Japan
[3] Pfizer R&D Japan GK, Shibuya Ku, Tokyo, Japan
[4] Pfizer Inc, New York, NY USA
[5] Tokyo Med & Dent Univ, Bunkyo Ku, Tokyo, Japan
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE180
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 50 条
  • [41] Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience
    Giusy Tiseo
    Chiara Barbieri
    Valentina Galfo
    Sara Occhineri
    Tommaso Matucci
    Francesco Almerigogna
    Jona Kalo
    Pietro Sponga
    Mario Cesaretti
    Gabriele Marchetti
    Arianna Forniti
    Claudio Caroselli
    Simone Ferranti
    Manuela Pogliaghi
    Marina Polidori
    Silvia Fabiani
    Stefano Verdenelli
    Enrico Tagliaferri
    Niccolò Riccardi
    Lorenzo Roberto Suardi
    Claudia Carmignani
    Serena Batini
    Luca Puccetti
    Riccardo Iapoce
    Francesco Menichetti
    Marco Falcone
    Infectious Diseases and Therapy, 2023, 12 : 257 - 271
  • [42] Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies
    Mesfin, Yonatan M.
    Blais, Joseph E.
    Kibret, Kelemu Tilahun
    Tegegne, Teketo Kassaw
    Cowling, Benjamin J.
    Wu, Peng
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (09) : 2119 - 2131
  • [43] Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase
    Wan, Eric Yuk Fai
    Wang, Boyuan
    Mathur, Sukriti
    Chan, Cheyenne I. Ying
    Yan, Vincent Ka Chun
    Lai, Francisco Tsz Tsun
    Chui, Celine Sze Ling
    Li, Xue
    Wong, Carlos King Ho
    Li, Philip Hei
    Lau, Chak Sing
    Wong, Ian Chi Kei
    Chan, Esther Wai Yin
    JOURNAL OF INFECTION, 2023, 86 (06) : 622 - 625
  • [44] Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study
    Park, Jin Ju
    Kim, Hyunji
    Kim, Yong Kyun
    Lee, Seung Soon
    Jung, Eunju
    Lee, Jin Seo
    Lee, Jacob
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2023, 38 (42)
  • [45] Nirmatrelvir-ritonavir for nonhospitalized patients with COVID-19
    LeBras, Marlys
    Crawley, Alex
    Legge, Marc
    Takaya, Satchan
    Lee, Stephen
    Regier, Loren
    CANADIAN FAMILY PHYSICIAN, 2023, 69 (08) : 546 - 549
  • [46] Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients
    Haddad, Andrea J.
    Hachem, Ray Y.
    Moussa, Mohamed
    Jiang, Ying
    Dagher, Hiba R.
    Chaftari, Patrick
    Chaftari, Anne-Marie
    Raad, Issam I.
    CANCERS, 2024, 16 (05)
  • [47] Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients
    Cowman, Kelsie
    Miller, Alexander
    Guo, Yi
    Chang, Mei H.
    McSweeney, Terrence
    Bao, Hongkai
    Simpson, Roxanne
    Braithwaite, Claire
    Sunu, Evans
    Ros, Theary
    Rodriguez, Maria
    Laboy, Eric
    Bard, Linda
    Alsina, Leslie
    Cintron, Angelica
    Andrews, Erin
    Nori, Priya
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (07) : 1683 - 1688
  • [48] Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19
    Zhang, Huan
    Tan, Xiaojiao
    Chen, Junjun
    Zhang, Zheng
    Wang, Chenxi
    Shi, Haiqing
    Li, Yao
    Li, Jianbo
    Kang, Yan
    Jin, Xiaodong
    Liao, Xuelian
    BMJ OPEN RESPIRATORY RESEARCH, 2024, 11 (01)
  • [49] Nirmatrelvir plus ritonavir remains effective in vaccinated patients at risk of progression with COVID-19: A systematic review and meta-analysis
    Li, Huamin
    Xiang, Huairong
    He, Bei
    Zhang, Qizhi
    Peng, Wenxing
    JOURNAL OF GLOBAL HEALTH, 2023, 13
  • [50] Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes
    Ma, Bosco Hon-Ming
    Yip, Terry Cheuk-Fung
    Lui, Grace Chung-Yan
    Lai, Mandy Sze-Man
    Hui, Elsie
    Wong, Vincent Wai-Sun
    Tse, Yee-Kit
    Chan, Henry Lik-Yuen
    Hui, David Shu-Cheong
    Kwok, Timothy Chi-Yui
    Wong, Grace Lai-Hung
    JAMA NETWORK OPEN, 2023, 6 (04) : E2310887
12345